MedPath

A Multicenter Observational Study of Whole Genome Analysis for patient benefit

Not Applicable
Recruiting
Conditions
cancer
Registration Number
JPRN-UMIN000049428
Lead Sponsor
ational Cancer Center Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
5000
Inclusion Criteria

Not provided

Exclusion Criteria

none

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of patients with advanced or refractory cancer linked to treatment after whole genome analysis
Secondary Outcome Measures
NameTimeMethod
Percentage of patients who will be diagnosed after whole genome analysis in particularly difficult-to-diagnose cancer types, including rare cancers. Percentage of patients for whom a heritable disease-associated pathological variant is extracted by whole genome analysis
© Copyright 2025. All Rights Reserved by MedPath